Goldman Sachs’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$116M Buy
2,105,605
+512,642
+32% +$28.2M 0.02% 689
2025
Q1
$113M Buy
1,592,963
+1,083,512
+213% +$76.6M 0.02% 635
2024
Q4
$33.5M Buy
509,451
+59,485
+13% +$3.91M 0.01% 1362
2024
Q3
$31.6M Sell
449,966
-109,836
-20% -$7.72M 0.01% 1388
2024
Q2
$46.1M Sell
559,802
-133,422
-19% -$11M 0.01% 1042
2024
Q1
$60.5M Sell
693,224
-214,557
-24% -$18.7M 0.01% 893
2023
Q4
$87.5M Sell
907,781
-71,814
-7% -$6.92M 0.02% 720
2023
Q3
$86.7M Sell
979,595
-455,302
-32% -$40.3M 0.02% 680
2023
Q2
$124M Buy
1,434,897
+306,018
+27% +$26.5M 0.03% 537
2023
Q1
$110M Sell
1,128,879
-42,172
-4% -$4.1M 0.03% 571
2022
Q4
$121M Buy
1,171,051
+388,026
+50% +$40.2M 0.03% 537
2022
Q3
$66.4M Sell
783,025
-39,673
-5% -$3.36M 0.02% 799
2022
Q2
$68.2M Buy
822,698
+114,080
+16% +$9.45M 0.02% 788
2022
Q1
$54.6M Sell
708,618
-106,449
-13% -$8.21M 0.01% 1015
2021
Q4
$72M Sell
815,067
-671,512
-45% -$59.3M 0.01% 875
2021
Q3
$115M Buy
1,486,579
+235,441
+19% +$18.2M 0.02% 579
2021
Q2
$104M Buy
1,251,138
+38,296
+3% +$3.2M 0.02% 616
2021
Q1
$91.6M Sell
1,212,842
-393,128
-24% -$29.7M 0.02% 631
2020
Q4
$141M Sell
1,605,970
-76,103
-5% -$6.67M 0.04% 391
2020
Q3
$128M Sell
1,682,073
-226,417
-12% -$17.2M 0.04% 416
2020
Q2
$235M Buy
1,908,490
+225,983
+13% +$27.9M 0.07% 229
2020
Q1
$142M Buy
1,682,507
+69,790
+4% +$5.9M 0.05% 336
2019
Q4
$136M Buy
1,612,717
+143,113
+10% +$12.1M 0.03% 499
2019
Q3
$99.1M Sell
1,469,604
-498,011
-25% -$33.6M 0.03% 608
2019
Q2
$169M Sell
1,967,615
-207,951
-10% -$17.8M 0.05% 404
2019
Q1
$193M Buy
2,175,566
+146,363
+7% +$13M 0.06% 343
2018
Q4
$173M Sell
2,029,203
-305,226
-13% -$26M 0.06% 334
2018
Q3
$226M Sell
2,334,429
-407,815
-15% -$39.5M 0.06% 334
2018
Q2
$258M Sell
2,742,244
-484,416
-15% -$45.6M 0.07% 271
2018
Q1
$262M Buy
3,226,660
+361,158
+13% +$29.3M 0.07% 291
2017
Q4
$256M Buy
2,865,502
+506,352
+21% +$45.2M 0.06% 312
2017
Q3
$220M Buy
2,359,150
+395,081
+20% +$36.8M 0.05% 323
2017
Q2
$178M Buy
1,964,069
+424,610
+28% +$38.6M 0.05% 398
2017
Q1
$135M Buy
1,539,459
+158,527
+11% +$13.9M 0.04% 483
2016
Q4
$114M Buy
1,380,932
+49,132
+4% +$4.07M 0.03% 561
2016
Q3
$123M Buy
1,331,800
+641,098
+93% +$59.3M 0.04% 505
2016
Q2
$53.7M Sell
690,702
-153,605
-18% -$12M 0.02% 869
2016
Q1
$69.6M Sell
844,307
-221,233
-21% -$18.2M 0.02% 719
2015
Q4
$112M Buy
1,065,540
+671,252
+170% +$70.3M 0.04% 491
2015
Q3
$41.5M Buy
394,288
+140,873
+56% +$14.8M 0.01% 907
2015
Q2
$34.7M Sell
253,415
-674,687
-73% -$92.3M 0.01% 1069
2015
Q1
$116M Buy
928,102
+513,073
+124% +$63.9M 0.04% 456
2014
Q4
$37.5M Sell
415,029
-37,405
-8% -$3.38M 0.01% 979
2014
Q3
$32.6M Sell
452,434
-505,079
-53% -$36.4M 0.01% 1015
2014
Q2
$59.6M Buy
957,513
+360,399
+60% +$22.4M 0.02% 734
2014
Q1
$40.7M Sell
597,114
-129,842
-18% -$8.86M 0.01% 887
2013
Q4
$51.1M Sell
726,956
-581,701
-44% -$40.9M 0.02% 747
2013
Q3
$94.4M Sell
1,308,657
-101,098
-7% -$7.3M 0.03% 460
2013
Q2
$78.6M Buy
+1,409,755
New +$78.6M 0.03% 479